These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29305171)

  • 1. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
    Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
    Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
    Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
    Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
    Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S; Li Y; Cao X; Du J; Huang X
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
    Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
    Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.
    Lager TW; Roetman JJ; Kunkel J; Thacker M; Sheets JN; Egland KA; Miles CM; Larson MK; Gubbels JAA
    Platelets; 2018 Dec; 29(8):834-837. PubMed ID: 30335544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human chorionic gonadotropin β regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer.
    Liu N; Peng SM; Zhan GX; Yu J; Wu WM; Gao H; Li XF; Guo XQ
    Oncol Rep; 2017 Sep; 38(3):1464-1472. PubMed ID: 28713970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of SLC7A1 in high-grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT.
    You S; Han X; Xu Y; Sui L; Song K; Yao Q
    Cancer Med; 2024 May; 13(10):e7217. PubMed ID: 38752472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
    Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
    J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
    Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
    Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
    Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial‑mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.
    Wang Y; Yang B; Zhao J; Yu X; Liu X; Zhang L; Zhang Y; Li X; Zhai Z
    Mol Med Rep; 2019 Mar; 19(3):1501-1508. PubMed ID: 30628686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migration and Platinum Resistance by Rescuing Hedgehog-Mediated Autophagy.
    Ferraresi A; Esposito A; Girone C; Vallino L; Salwa A; Ghezzi I; Thongchot S; Vidoni C; Dhanasekaran DN; Isidoro C
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831435
    [No Abstract]   [Full Text] [Related]  

  • 15. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
    J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells.
    Zhou Y; Zhu Y; Fan X; Zhang C; Wang Y; Zhang L; Zhang H; Wen T; Zhang K; Huo X; Jiang X; Bu Y; Zhang Y
    Oncotarget; 2017 May; 8(20):33110-33121. PubMed ID: 28416770
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Sheets JN; Patrick ME; Egland KA
    Oncotarget; 2020 Jun; 11(24):2290-2301. PubMed ID: 32595828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.